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Introduction: 
The development organometallic chemistry of 
cross-coupling reactions represents a pattern 
shift in chemical synthesis, and today synthetic 
chemists can willingly access C-C/C-N/C-O/
C-S and other carbon-heteroatom bonds from a 
vast collection of starting compounds. Although 
we cannot understate the importance of these 
methods, the required pre-functionalization to 
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Abstract: This manuscript describes the design and synthesis of a series of diverse N-Acyl Anthranil-
amides and quinazolin-4-ones derivatives (3a-3n, and 4a-4d) inhibitors of HMG-CoA reductase for the 
treatment of hypercholesterolemia. A series of N-Acyl Anthranilamides and quinazolin-4-ones derivatives 
(3a-3n, and 4a-4d) were synthesized and their chemical structures were confirmed by 1 H, 13C NMR and 
mass spectral data. Analogs were optimized using structure-based design and physical property consider-
ations resulting in the identification of 4b and 3d, a hepatoselective HMG-CoA reductase inhibitor with 
excellent acute and chronic efficacy in a vitro model. 
Keywords: hypercholesterolemia, HMG-CoA reductase, Molecular docking, N-Acyl Anthranilamides and 
quinazolin-4-ones derivatives. 
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carry out these reactions adds cost and reduces 
the availability of the starting reagents. The 
Pd-catalyzed cascade reactions with C-C/C-
N/C-O/C-S and other carbon-heteroatom bond 
formation have made a immense involvement 
to the current development of organic 
synthesis.1Recently, much attention has been 
paid toward the development of Pd-catalyzed 
insertion reactions, in which isocyanides is 
inserted between the two coupling partners due 
to the capability of Pd- metal complex to react 
with the π-system of isocyanide.2  
on the other hand, isocyanides, which are 
isoelectronic with carbon monoxide, has been 
used as synthetic surrogates of CO in Pd-
catalyzed tandem reaction due to the potential of 
transition metal complex to react with л-system 
of isocyanides. In this context, a broad range 
of heterocycles has been synthesized using 
isocyanides instead of CO in transition metal 
catalyzed tandem reactions.3 
 
Recently, Ji et. al. accounted a Pd-catalyzed 
synthesis of isocoumarins and phthalides via 
isocyanide insertion.4 We have also developed 
a diversity oriented synthesis of isoquinolines-
one and isoindolinone via the ligand free Pd-
catalyzed coupling cascade reaction with 
insertion of isocyanides into amide.5,6 Inspired 
by the above literature and our previous report, 
we envisaged that the insertion of isocyanides 
into amide to synthesize substituted N-Acyl 
Anthranilamide and quinazolin-4-one 
derivatives might be possible (Scheme 1). 
The atom-economical synthesis of N-acyl 
anthranilamides from readily available anilides 
and isocyanates is of significant practical utility 
given that this structural motif is found in 
numerous drugs and drug candidates7(Figure 
1). Anthranilamides are typically prepared from 
the corresponding anthranilic acids; however, 
this approach is inherently restricted by the 
limited selection of commercially available 
anthranilic acids8. Moreover, both N-acyl 
anthranilamides and enamine amides are 
poised to undergo cyclodehydration reactions 
to provide quinazolinone and pyrimidinone 
frameworks, which are also a common feature 
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Scheme 1. our approaches using isocyanides 




























 Figure 1. Some biologically active molecules 
and natural products containing N-Acyl 
anthranilamide, quinazolin-4-one motif. 
Quinazolinone is a building block of naturally 
occurring alkaloids and utilized as a drug 
like scaffold in several natural products10-14 
(Trypanthrine, rutaecarpine and luotonin 
A, Figure 1), as these possess a wide range 
of biological activities including antitumor, 
anticonvulsant,15 antiviral,16 antiinflammatory, 
analgesic,17 antimicrobial,18 antifungal,19 
antimalarial, antidiabetic,20  cytotoxicity21 
and angiotensin II AT1 receptor antagonists.22 
Recently we have developed an efficient and 
facile methodology for the preparation of this 
privileged quinazolinone scaffold.23   
It is generally recognized that 
hypercholesterolemia and high levels of serum 
LDL-cholesterol contribute significantly to 
the progression of atherosclerosis24 which is 
the leading cause of cardiovascular diseases. 
Liver enzyme 3-hydroxy-3-methylglutaryl- 
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coenzyme A (HMG-CoA) reductase (HMGR) 
catalyzes the formation of mevalonate, the 
key step in the biosynthesis of cholesterol and 
isoprenoids.25 Therefore, inhibition of this 
enzyme has proven to be the most efficient 
therapy for hyperlipidemia.26
Owing to the synthetic importance of N-Acyl 
Anthranilamide and quinazolin-4-one, based on 
our continuing interest towards the synthesis 
of biologically important heterocycles using 
isocyanide based chemistry, herein, we disclose 
a Pd-catalyzed tandem C-C/C-N coupling 
reaction affording a variety of functionalized 
N-Acyl Anthranilamide and quinazolin-4-one 
derivatives in high yields using amide and 
isocyanides as coupling partner. Here we are 
also going to disclose the (HMG-CoA) reductase 
inhibitory potential of these compounds. 
Experimental
General information:
All reagents and solvents were purchased 
from commercial sources and used without 
purification. NMR spectra were recorded with 
300 MHz spectrometers for 1H NMR and 50 
MHz for 13C NMR on Bruker Supercon Magnet 
Avance DRX-300 spectrometers in deuterated 
solvents with TMS as internal reference 
(chemical shifts δ in ppm, coupling constant J 
in Hz.). Multiplicities are reported as follows: 
singlet (s), doublet (d), triplet (t), multiplet 
(m), and broad singlet (br s). Mass spectra 
and HRMS were taken in the ESI positive ion 
mode. The reaction progress was monitored by 
thin layer chromatography (TLC) on pre-coated 
silica gel plates. Column chromatography was 
performed over Merck silica gel (230-400 
flash). All compounds were characterized by 
TLC, 1H NMR and 13C NMR, MS and HRMS.
General Procedure for the synthesis of 
substituted isoindolines 3a-n: 
Amide 3 (1 mmol), isocyanide 2 (1.2mmol), 
Pd(OAc)2 (10 mol %), Cs2CO3 (2 mmol.), 
PPh3(10 mol %) and DMF/H20 ( 10/1 ,2 mL) as 
a solvent were added in a 10 mL reaction glass 
vial containing a stirring bar under the nitrogen 
atmosphere, the vial was sealed tightly with a 
Teflon cap and placed in microwave cavity for 
15 min at a pre-selected temperature of 120 °C. 
After completion of the reaction as indicated by 
TLC, the resulting mixture was filtered through 
a pad of celite, and the celite was rinsed with 
EtOAc. The solvent was evaporated under 
reduced pressure and the residue was purified 
by flash column chromatography on silica 
gel (eluent: hexane/ EtOAc) affording the 
corresponding coupling product 3a-n in 85-
71% yields. 
General Procedure for the synthesis of 
substituted isoindolines 4a-d: 
Amide 3 (1 mmol), isocyanide 2 (1.2mmol), 
Pd(OAc)2 (10 mol %), Cs2CO3 (2 mmol.), 
PPh3(10 mol %) and DMF/H20 ( 10/1 ,2 mL) as 
a solvent were added in a 10 mL reaction glass 
vial containing a stirring bar under the nitrogen 
atmosphere, the vial was sealed tightly with a 
Teflon cap and placed in microwave cavity for 
45 min at a pre-selected temperature of 160 °C. 
After completion of the reaction as indicated by 
TLC, the resulting mixture was filtered through 
a pad of celite, and the celite was rinsed with 
EtOAc. The solvent was evaporated under 
reduced pressure and the residue was purified 
by flash column chromatography on silica 
gel (eluent: hexane/ EtOAc) affording the 




Solid, Yield = 76%, mp = 143-146 0C, FT-IR 
(KBr) ν (cm-1): 3425, 2946, 2324, 1627, 1106, 
759, 1H NMR (400 MHz, CDCl3): δ 11.95 (br 
s, 1H), 8.77 (d, J = 8.4 Hz, 1H), 8.06-8.04 (m, 
2H), 7.58-7.44 (m, 5H), 7.09 (t, J = 7.2 Hz, 1H), 
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6.16 (br s, 1H), 1.52 (s, 9H) ppm, 13C NMR 
(100 MHz, CDCl3): 169.0, 165.5, 139.5, 134.8, 
132.2, 131.7, 128.7, 127.4, 126.4, 122.7, 122.3, 
121.6, 52.2, 28.7 ppm, HRMS (ESI) Calcd. for 
C18H20N2O2 [M+H]
+ 297.1525 Found 297.1595.
2-benzamido-N-(2,4,4-trimethylpentan-2-yl)
benzamide (3b) -
Solid, Yield = 71%, mp = 123-125 0C  FT-IR 
(KBr) ν (cm-1): 3413, 2948, 2356, 1647, 1026, 
762, 1H NMR (400 MHz, CDCl3): δ 11.9 (br s, 
1H), 8.76 (d, J = 8.0 Hz, 1H), 8.05 (d, J = 6.8 
Hz, 2H), 7.58-7.42 (m, 5H), 7.08 (t, J = 7.2 Hz, 
1H), 6.20 (br s, 1H), 1.92 (s, 2H), 1.57 (s, 6H), 
1.07 (s, 9H) ppm, 13C NMR (100 MHz, CDCl3): 
168.8, 165.4, 139.3, 134.8, 132.0, 131.7, 128.7, 
127.3, 126.3, 122.8, 122.7, 121.7, 56.1, 51.5, 
31.7, 31.5, 29.1 ppm, HRMS (ESI) Calcd. for 
C22H28N2O2 [M+H]
+ 353.2151 Found 353.2221.
.2-benzamido-N-cyclohexylbenzamide (3c) 
-Solid, Yield = 83%, mp = 121-123 0C, FT-IR 
(KBr) ν (cm-1): 3434, 2903, 2322, 1627, 1146, 
789, 1H NMR (300 MHz, CDCl3): δ 12.0 (br s, 
1H), 8.77 (d, J = 8.1 Hz, 1H), 8.05 (d, J = 5.7 
Hz, 2H), 7.55-7.49 (m, 5H), 7.05 (t, J = 7.2 Hz, 
1H), 6.43 (br s, 1H), 4.00-3.97 (m, 1H), 2.07-
2.04 (m, 2H), 1.81-1.67 (m, 3H), 1.51-1.21 (m, 
5H) ppm, 13C NMR (75 MHz, CDCl3): 168.3, 
165.5, 139.7, 134.8, 132.4, 131.8, 128.7, 127.3, 
126.6, 122.7, 121.5, 121.0, 48.8, 33.0, 25.4, 
24.9 ppm, HRMS (ESI) Calcd. for C20H22N2O2 
[M+H]+ 323.1681 Found 323.1751
N-(2-(tert-butylcarbamoyl)phenyl)-3,4,5-
trimethoxybenzamide (3d) -
Solid, Yield = 78%, mp = 103-105 0C, FT-IR 
(KBr) ν (cm-1): 3315, 2903, 2334, 1605, 1106, 
769,  1H NMR (400 MHz, CDCl3): δ 12.1 (br s, 
1H), 8.79 (d, J = 8.4, 1H), 7.51-7.43 (m, 2H), 
7.32 (s, 2H), 7.08 (t, J = 7.6 Hz, 1H), 6.13 (br 
s, 1H), 3.97 (s, 6H), 3.92 (s, 3H), 1.49 (s, 9H) 
ppm.169.3, 165.2, 153.3, 141.2, 140.1, 132.6, 
130.4, 126.6, 122.8, 121.7, 121.4, 104.8, 61.1, 
56.3, 52.4, 28.9 ppm, HRMS (ESI) Calcd. for 
C21H26N2O5 [M+H]
+ 387.1842 Found 387.1917.
N-(2-(cyclohexylcarbamoyl)phenyl)-3,4,5-
trimethoxybenzamide (3e) -
Solid, Yield = 75%, mp = 113-115 0C, FT-IR 
(KBr) ν (cm-1): 3422, 2913, 2304, 1627, 1026, 
749,  1H NMR (300 MHz, CDCl3): δ 12.1 (s, 
1H), 8.88-8.47 (m, 1H), 7.54-7.48 (m, 2H), 7.30 
(s, 2H), 7.11 (t, J = 9.6 Hz, 1H), 6.28 (br s, 1H), 
3.98 (s, 6H), 3.93 (s, 3H), 2.05-2.02 (m, 2H), 
1.80-1.66 (m, 3H), 1.49-1.20 (m, 5H) ppm, 13C 
NMR (75 MHz, CDCl3): 168.3, 165.2, 153.2, 
141.0, 139.8, 132.5, 130.3, 126.4, 122.7, 121.3, 
120.9, 104.7, 60.9, 56.2, 48.8, 32.9, 25.4, 24.8 
ppm,  HRMS (ESI) Calcd. for C23H28N2O5 
[M+H]+ 413.1998 Found 413.2073.
N-tert-butyl-2-(4-methoxybenzamido)
benzamide (3f) -
Solid, Yield = 83%, mp = 123-125 0C, FT-IR 
(KBr) ν (cm-1): 3315, 2947, 2314, 1657, 1166, 
783,  1H NMR (400 MHz, CDCl3): δ 11.78 (s, 
1H), 8.69 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.8 Hz, 
2H), 7.44-7.39 (m, 2H), 7.00-6.94 (m, 3H), 6.29 
(br s, 1H), 3.86 (s, 3H), 1.50 (s, 9H) ppm, 13C 
NMR (100 MHz, CDCl3): 169.3, 165.2, 162.6, 
139.7, 132.2, 129.4, 127.4, 126.8, 122.6, 122.4, 
121.6, 114.1, 55.6, 52.3, 28.7 ppm, HRMS 
(ESI) Calcd. for C19H22N2O3 [M+H]
+ 327.1630 
Found 327.1705..
N-ter t -buty l -2 - (4 - f luorobenzamido)
benzamide (3g) -
Solid, Yield = 76%, mp = 128-130 0C, FT-IR 
(KBr) ν (cm-1): 3407, 2923, 2304, 1627, 1026, 
765, 1H NMR (400 MHz, CDCl3): δ 11.9 (s, 
1H), 8.72 (d, J = 8.4, 1H), 8.05-8.02 (m, 2H), 
7.49-7.42 (m, 2H), 7.20 (t, J = 8.4 Hz, 2H), 
7.06 (t, J = 7.6 Hz, 1H), 6.19 (br s, 1H), 1.50 (s, 
9H) ppm, 13C NMR (100 MHz, CDCl3): 169.2, 
164.5, 139.7, 132.4, 131.3, 131.2, 130.0, 129.9, 
126.7, 123.0, 122.2, 121.7, 116.0, 115.8, 52.4, 
28.9 ppm, HRMS (ESI) Calcd. for C18H19FN2O2 
[M+H]+ 315.1431 Found 315.1506.
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N-tert -buty l -2 - (3 -ch lorobenzamido)
benzamide (3h) -
Solid, Yield = 82%, mp = 133-135 0C, FT-IR 
(KBr) ν (cm-1): 3435, 2933, 2344, 1648, 1121, 
749, 1H NMR (400 MHz, CDCl3): δ 12.0 (s, 
1H), 8.69 (s, J = 8.4 Hz, 1H), 8.03 (s, 1H), 7.87 
(d, J = 7.6 Hz, 1H), 7.53-7.42 (m, 4H), 7.04 (t, J 
= 7.6 Hz, 1H), 6.33 (br s, 1H), 1.53 (s, 9H) ppm, 
13C NMR (100 MHz, CDCl3):  169.2, 164.3, 
139.3, 136.9, 135.1, 132.3, 131.9, 130.2, 128.3, 
126.8, 125.2, 123.2, 122.4, 121.7, 52.4, 28.9 
ppm, HRMS (ESI) Calcd. for C18H19ClN2O2 
[M+H]+ 331.1135 Found 331.1212.
2 - b e n z a m i d o - N - t e r t - b u t y l - 3 , 5 -
dimethylbenzamide (3i) -
Solid, Yield = 79%, mp = 106-108 0C, FT-IR 
(KBr) ν (cm-1): 3415, 2903, 2214, 1617, 1123, 
789, 1H NMR (400 MHz, CDCl3): δ 9.88 (s, 
1H), 8.16 (d, J = 7.5 Hz, 2H), 7.58-7.46 ( m, 
3H), 7.00 (s, 1H), 6.95 (s, 1H), 6.50 (br s, 1H), 
2.25 (s, 3H), 2.19 (s, 3H), 1.25 (s, 9H) ppm, 13C 
NMR (100 MHz, CDCl3): 169.2, 167.4, 136.6, 
136.5, 135.4, 133.8, 132.6, 131.7, 130.3, 128.4, 
127.8, 125.3, 51.6, 28.4, 20.8, 18.4 ppm, HRMS 
(ESI) Calcd. for C20H24N2O2 [M+H]
+ 325.1838 
Found 325.1912.
N - t e r t - b u t y l - 2 - b u t y r a m i d o - 3 , 5 -
dimethylbenzamide (3j) -
Solid, Yield = 77%, mp = 144-146 0C, FT-IR 
(KBr) ν (cm-1): 3410, 2940, 2334, 1608, 1174, 
761, 1H NMR (300 MHz, CDCl3): δ 8.93 (s, 1H), 
6.96 (d, J = 10.5 Hz, 2H), 6.37 (br s, 1H), 2.38 (t, 
J = 7.2 Hz, 3H), 2.23 (s, 3H), 2.12 (s, 3H), 1.87-
1.72 (m, 2H), 1.41 (s, 9H), 1.04 (t, J = 6.6 Hz, 
3H) ppm,  13C NMR (75 MHz, CDCl3):173.2, 
169.2, 136.2, 136.1, 134.7, 132.7, 130.3, 125.2, 
51.6, 38.7, 28.5, 20.7, 19.4, 18.4, 14.0 ppm, 
HRMS (ESI) Calcd. for C17H26N2O2 [M+H]
+ 
291.1994 Found 291.2070. 
N-tert-butyl-2-butyramidobenzamide (3k) 
-Solid, Yield = 81%, mp = 113-115 0C , FT-IR 
(KBr) ν (cm-1): 3411, 2913, 2304, 1637, 1120, 
782, 1H NMR (400 MHz, CDCl3): 10.8 (br s, 
1H), 8.4 (s, 1H), 7.39 (t, J = 5.4 Hz, 2H), 7.00 (s, 
J = 5.4 Hz, 1H), 6.16 (br s, 1H), 2.35 (t, J = 7.2 
Hz, 2H), 1.76 (t, J = 7.2 Hz, 2H), 1.45 (s, 9H), 
1.29-1.26 (m, 2H), 1.02-0.96 (m, 3H) ppm, 13C 
NMR (75 MHz, CDCl3): 172.1, 169.0, 139.2, 
132.1, 126.7, 122.6, 122.4, 121.7, 52.2, 40.5, 
28.9, 19.2, 13.9 ppm, HRMS (ESI) Calcd. for 
C15H22N2O2 [M+H]
+ 263.1681 Found 263.1757.
N-tert-butyl-2-pentanamidobenzamide (3l) -
Solid, Yield = 78%, mp = 122-124 0C, FT-IR 
(KBr) ν (cm-1): 3422, 2918, 2319, 1602, 1066, 
765,  1H NMR (400 MHz, CDCl3): 10.8 (s, 1H), 
8.52 (d, J = 8.4 Hz, 1H), 7.51-7.36 (m, 2H), 
7.03 (t, J = 7.6 Hz, 1H), 6.16 (br s, 1H), 2.40 
(t, J = 7.6 Hz, 2H), 1.76-1.64 (m, 2H), 1.48 (s, 
9H), 1.45-1.36 (m, 2H), 0.97 (t, J = 7.6 Hz, 3H) 
ppm, 13C NMR (75 MHz, CDCl3): 172.1, 168.8, 
139.1, 131.9, 126.4, 122.4, 122.2, 121.5, 52.0, 
38.1, 28.7, 27.6, 22.3, 13.7 ppm, HRMS (ESI) 
Calcd. for C16H24N2O2 [M+H]
+ 277.1838 Found 
277.1904.
N-tert-butyl-2-pivalamidobenzamide (3m) -
Solid, Yield = 85%, mp = 107-109 0C, FT-IR 
(KBr) ν (cm-1): 3411, 2903, 2214, 1614, 1146, 
769,  1H NMR (400 MHz, CDCl3): 10.9 (br s, 
1H), 8.53 (t, J = 4.8 Hz, 1H), 7.43-7.37 (m, 2H), 
7.04-7.00 (m, 1H), 6.05 ( br s, 1H), 1.48 (s, 9H), 
1.32 (s, 9H) ppm, 13C NMR (75 MHz, CDCl3): 
177.5, 169.0, 139.1, 131.7, 126.2, 123.0, 122.4, 
121.6, 52.0, 31.5, 28.6, 27.5 ppm,  HRMS (ESI) 
Calcd. for C16H24N2O2 [M+H]




Solid, Yield = 79%, mp = 127-129 0C  FT-IR 
(KBr) ν (cm-1): 3348, 2947, 2304, 1619, 1026, 
749, 1H NMR (400 MHz, CDCl3): 10.9 (br s, 
1H), 8.56 (d, J = 8.4 Hz, 1H), 7.45-7.36 (m, 
2H), 7.06 (t, J = 7.2 Hz, 1H), 5.98 (br s, 1H), 
1.90 (s, 2H), 1.53 (s, 6H), 1.33 (s, 9H), 1.06 (s, 
9H), 13C NMR (75 MHz, CDCl3): 177.5, 168.7, 
Chemistry & Biology Interface Vol. 9 (3), May – June 2019177
Chemistry & Biology Interface, 2019, 9, 3, 172-185
139.1, 131.7, 126.0, 123.2, 122.5, 121.7, 56.0, 
51.3, 31.5, 29.2, 27.5, 22.6, 14.0 ppm,  HRMS 




Solid, Yield = 84%, mp = 176-178 0C  FT-IR 
(KBr) ν (cm-1): 3425, 2943, 2354, 1637, 1123, 
761, 1H NMR (400 MHz, DMSO-d6): 12.5 (br s, 
1H), 8.20 (t, J = 8.4 Hz, 3H), 7.86 (t, J = 7.6 Hz, 
1H), 7.76 (d, J = 8.0 Hz, 1H), 7.59-7.50 (m, 4H) 
ppm, 13C NMR (100 MHz, DMSO-d6): 162.7, 
152.7, 149.2, 135.0, 133.1, 131.8, 129.0, 128.2, 
127.9, 127.0, 126.3, 121.4 ppm, HRMS (ESI) 
Calcd. for C14H10N2O [M+H]




Solid, Yield = 81%, mp = 182-184 0C  FT-
IR (KBr) ν (cm-1): 3414, 2913, 2354, 1627, 
1106, 779, Yield = 61%, 1H NMR (400 MHz, 
DMSO-d6): 8.58 (d, J = 8.4 Hz, 1H), 8.37 (br 
s, 1H) 7.64-7.62 (m, 2H), 7.26-7.22 (m, 1H), 
7.16 (s, 2H), 3.95 (s, 6H), 3.93 (s, 3H) ppm, 
13C NMR (100 MHz, DMSO-d6): 165.3, 153.7, 
142.1, 140.9, 134.5, 132.2, 129.2, 124.4, 121.1, 
116.7, 104.7, 102.3, 61.1, 56.5 ppm, HRMS 





Solid, Yield = 74%, mp = 173-175 0C  FT-IR 
(KBr) ν (cm-1): 3315, 2933, 2324, 1604, 1026, 
761, 1H NMR (400 MHz, DMSO-d6): δ 12.4 
(brs, 1H), 8.21-8.13 (m, 3H), 7.84 (t, J=8.4 
Hz, 1H), 7.72 (d, J=8.0 Hz, 1H), 7.51 (t, J=8.0 
Hz, 1H), 7.10 (d, J=8.8 Hz, 2H), 3.88 (s, 3H) 
ppm, 13C NMR (100 MHz, DMSO-d6): δ 162.3, 
161.8, 151.8, 148.9, 134.5, 129.4, 127.3, 126.1, 
125.7, 124.7, 120.7, 113.9, 55.4 ppm, HRMS 





Solid, Yield = 81%, mp = 165-167 0C  FT-IR 
(KBr) ν (cm-1): 3425, 2943, 2344, 1629, 1124, 
789, 1H NMR (400 MHz, DMSO-d6): δ 12.5 (br 
s, 1H), 8.31-8.24 (m, 2H), 8.16 (d, J = 8.0 Hz, 
1H), 7.86-7.22 (m, 1H), 7.75 (d, J = 8.4 Hz, 1H), 
7.54 (t, J = 7.2 Hz, 1H), 7.41 (t, J = 8.8 Hz, 2H) 
ppm, 13C NMR (100 MHz, DMSO-d6): 122.6, 
151.8, 149.1, 135.1, 130.9, 130.8, 129.7, 127.9, 
127.0, 126.3, 121.3, 116.2, 115.9 ppm, HRMS 
(ESI) Calcd. for C14H9FN2O [M+H]
+ 241.6999 
Found 241.0774.
Biological Materials and Methods: 
In vitro HMG-CoA reductase inhibitory 
activity:  The HMG-CoA reductase assay was 
performed using the HMG-CoA reductase assay 
kit from SigmaeAldrich. HMG-CoA (substrate), 
NADPH, assay buffer and enzyme HMGR were 
supplied with the assay kit.
Cell culture and adipogenic differentiation:
3T3-L1 mouse embryo fibroblasts cell line 
was obtained from the American Type Culture 
Collection. Cells were cultured in a humidified 
atmosphere at 37ºC and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 
10% (v/v) heat-inactivated fetal bovine serum 
and antibiotic penicillin and streptomycin. For 
adipogenesis induction 50000 cells were seed in 
24 multi-well plates. After 2 days of when cells 
achieved near complete confluence, culture 
media was replaced with adipogenesis media I 
(containing Insulin 5 µg/ml, IBMX 0.5 mM and 
Dexamethasone 250 nm in culture medium). 
This media was then replaced after 72 hours 
with adipogenesis media II (Insulin 5 µg/ml in 
DMEM with 10% FBS).After replacement of 
this media, cells were then maintained next 2 
days in 10% FBS containing DMEM medium. 
Lipid globules in the adipogenic cells starts 
forming from day 4th onwards after treatment, 
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and fully developed adipocytes were observed 
after day 6-8th of adipogenesis treatment. More 
than 90% cells do have lipid globules at this 
stage.
Triglyceride assay and Oil Red O staining:
To study effect of compound on adipogenic 
differentiation, cells were differentiated as 
mentioned in above protocol along-with 
compound at stated concentrations.  Fully 
differentiated 3T3-L1 (with or without 
compound) adipocytes were rinsed in phosphate 
buffered saline (pH 7.4). The adipocytes lipid 
globules were stained with Oil Red O (0.36% 
in 60% Isopropanol) for 20 min. Unstained Oil 
Red O was removed by rinsing wells twice with 
phosphate buffer saline. After complete removal 
of PBS, finally, 100% Isopropanol was used to 
extract the dye from the cells and extracted dye 
absorbance was measured at 492 nm.
Results and discussion
Chemistry
Based on our research interest in palladium 
catalysis, we found a few reported 
examples concerning palladium-catalyzed 
aminocarbonylation for the synthesis of 
amides from aryl halides.27 However; the use 
of toxic carbon monoxide limited the scope of 
this kind of reaction.we initiated the study by 
using amide 1a and tert-butyl isocyanide 2a 
as a model substrates for the optimization of 
palladium-catalyzed tandem C-C/C-N coupling 
reaction. The investigation was carried out using 
different catalysts, base and solvents (Table 1). 
The reaction failed to proceed when palladium 
was expelled from the reaction (Table 1, entry 
1). Among the three Pd-catalysts used (PdCl2, 
Pd(PPh)3 and Pd(OAc)2), Pd(OAc)2 was found to 
be the best and provided the product 3a in 89% 
yield in DMF as a solvent at 120 oC (Table 1, entry 
4). Furthermore, PdCl2 and Pd(PPh)3 furnished 
the inferior yields of product 3a (Table 1, entry 
2 and 3). We next tested the coupling reaction 
using various bases such as Cs2CO3, K2CO3, 
Na2CO3, K3PO4 and KO
tBu in DMF at 120 oC, 
with Pd(OAc)2 as a catalyst, among these bases 
Cs2CO3 was found to be the most effective base 
(Table 1, entry 4). Using Pd(OAc)2 as catalyst 
and Cs2CO3 as base in DMSO provided slightly 
poor yield of 3a (Table 1, entry 9), while using 
toluene and CH3CN under the same conditions 
furnished 3a in only poor yields (Table1, entry 
10 and 11). The procedure was unfavourable 
when base was omitted from the reaction (Table 
1, entry 12). Further optimization revealed 
that PPh3 was essential in this reaction as well. 
Without PPh3, the yield decreased to 71%.We 
next tested the aminocarbonylation reaction 
in the presence of different solvents. DMF/
H2O (10:1) was superior to any other solvents 
The efficacy of tandem C-C/C-N cyclization 
reaction was affected when loading of the 
catalyst was reduced from 10 mol % to 5 mol 
% (Table 1, entry 13). It is interesting to note 
that the reaction was completed within 15-20 
min under MW conditions at 120 oC, while in 
the absence of MW irradiations it took 4-5 h to 
reach the completion. 
Table 1. Investigation of the Reaction 

















Entry catalyst base solvent
yield 
% b
1     - Cs2CO3 DMF 0
c
2 PdCl2 Cs2CO3 DMF 57
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3 Pd(PPh3)4 Cs2CO3 DMF 62
4 Pd(OAc)2 Cs2CO3 DMF 89
5 Pd(OAc)2 K2CO3 DMF 59
6 Pd(OAc)2 K3PO4 DMF 41
7 Pd(OAc)2 KO
tBu DMF 32
8 Pd(OAc)2 Na2CO3 DMF 53
9 Pd(OAc)2 Cs2CO3 DMSO 74
10 Pd(OAc)2 Cs2CO3 Toluene 57
11 Pd(OAc)2 Cs2CO3 CH3CN 52
12 Pd(OAc)2       - DMF 0
d
13 Pd(OAc)2 Cs2CO3 DMF 39
e
aReaction conditions: substrate 1a (1 mmol), 
tert-butyl isocyanide 2a (1.2 mmol), catalyst 
(10 mol %), base (2 mmol), solvent (2 mL), 
reaction temperature (120 οC), reaction time (15 
min), bisolated yield, cno addition of catalyst, d 
no addition of base,  e loading of catalyst (5 mol 
%).
Scope of the strategy:
With acceptable conditions in hand (Table 
1, entry 4), we extended it to the synthesis of 
various substituted N-Acyl Anthranilamide (3a-
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Scheme 2. Direct efficient cyclodehydration 
of N-acyl anthranilamides to quinazolinone 
respectively.
Literature methods are available for the efficient 
cyclodehydration of N-acyl anthranilamides 
to quinazolinone, respectively. However, 
we postulated that by conducting the Pd- 
catalyzed reaction at high temperature, both the 
isocyanide coupling and cyclization might be 
accomplished in a single step. Indeed, heating 
amides 2a with tert-butyl isocyanide at 160 
0C in the With acceptable conditions directly 
provided the corresponding quinazolin-4-ones 
(4a- 4d) in good yields.
When monitored by 1H NMR, the initial 
N-acyl anthranilamideproduct (3a) are formed 
along with the heterocycles (4a) at early 
conversion. Notably, heating the isolated 
amide 3a in the absence of Pd(OAc)2 resulted 
in negligible conversion to 4a, suggesting 
that cyclodehydration of 3a to 4a is facilitated 
by the Pd- catalyzed rather than being solely 
thermally induced. Although the reaction did 
not proceed at 120 oC temperature, good yields 
were obtained at 160 0C.
Reaction mechanism
A plausible mechanism for the synthesis of 
quinazolin-4-one of type 4a is depicted in scheme 
3. Thus, oxidative insertion of Pd to the amide 
precursor 1a leads to the intermediate 5 which 
on insertion of t-butyl isocyanide leads to Pd(II) 
species 6. Intermediate 6 via intramolecular 
cyclization followed by subsequent reductive 
elimination provides species 7. Intermediate 7 
then undergo Mazurciewitcz-Ganesan type28 



































Scheme 3. Pd- catalyzed cascade reaction.
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Figure 3. Synthesis of substituted N-acyl anthranilamide via a Pd-catalyzed coupling reaction of 
amide 1a-n and different isocyanide 2.
aReaction conditions: Pd(OAc)2 (10 mol %), Cs2CO3 (2 mmol), DMF (2 mL), MW, 120 
οC, 
reaction time 20 min. Yields refer to isolated products.
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Effects of compound on HMG-CoA reductase 
inhibition and Binding site analysis via 
docking –
Mevalonic acid (3,5-dihydroxy-3-
methylpentanoic acid) is the unique precursor 
for mammalian sterol synthesis. Its synthesis is 
catalyzed by a two-step reductive deacylation 
of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) with the enzyme HMG-CoA 
reductase . Modulation of the functional level 
of HMG-CoA reductase is but one target in a 
complex regulatory strategy used to achieve 
cellular and whole body cholesterol homeostasis.
Currently, the most common method of treating 
hypercholesterolemia is the use of HMG-CoA 
reductase inhibitors, also known as statins. These 
drugs block the rate-limiting step of cholesterol 
biosynthesis, ultimately resulting in up-
regulation of the LDL-receptor and the clearing 
of low density lipoprotein (LDL) particles 
from the bloodstream.29 As a class, statins have 
proven remarkably safe and effective for both 
primary prevention of coronary heart disease 
and secondary prevention of coronary events.30 
To meet the challenge of finding novel HMG-
CoA reductase inhibitors with the efficacy and 
tolerability profiles needed to help patients 
achieve aggressive LDL reduction goals, we 
undertook a discovery effort to identify a novel 
class of inhibitors.
Figure.3 Percentage (%) inhibition of HMG-
CoA reductase by lactams.
The inhibitory activity was evaluated at 100 
µM (Fig. 3). Compound 3d, 3k, 4a and 4b were 
showing inhibition of HMG-CoA reductase at 
100 µM concentration. Compound 4b was most 
active. After that we investigated the binding 
affinity of compounds towards the HMG-CoA 
reductase via molecular docking experiment.
Docking protocol 
Autodok 4.231 has been used for molecular 
docking studies on four compounds 4b, 3d and 
3k respectively with HMG-CoA reductase by 
treating the ligand as conformationally flexible. 
Reference protein coordinates for docking were 
obtained from the X-ray structure of catalytic 
portion of human HMG-CoA reductase (HMGR) 
complexed with simvastatin (PDB id: 1HW9). 
First, water molecules of the receptor molecule 
were removed and hydrogens were added. A 
binding pocket of the receptor was selected as 
the 6.5 Å around the bound simvastatin for the 
study. Grid maps for each atom type in the ligand 
were generated by using the Autogrid utility in 
Autodok 4.2. The following specifications were 
used for the grids. Grid with three coordinates 
(X=30 Å ,Y=34 Å,Z= 34 Å) with grid spacing 
set to 0.375 Å  , was centred on the active 
site the centre having X, Y, and Z coordinates 
fixed at 3.928,-9.204 and -11.326  respectively. 
Docking was carried out with 20 GA runs, 
initial population size of 150 and 250000 
maximum number of energy evaluations and 
27000 maximum numbers of generations. Other 
docking parameters were set to default. Twenty 
conformations were generated for each ligand 
using Autodok 4.2. Docking simulations were 
performed using Autodok 4.2, implementing 
Lamarckian Genetic Algorithm (LGA). The 
interaction energies between the ligands and the 
HMG-CoA reductase calculated. The different 
docked conformations were ranked on the basis 
of their binding and docking energy scores and 
further analyzed for the possible interactions 
with the Protein. Molecular graphics images 
were produced using the PyMOL32. 
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Finally the docked ligand-receptor complexes 
were selected according to the criteria of 
interacting energies combined with the 
geometrical matching quality. These complexes 
were used to have a comparative account of 
activity and their structural conformations. The 
total binding and docking energies between 
the compound and receptor was calculated 
according to the algorithm in the Autodok 
4.2 programs. We found acceptable docking 
statistics with the HMG-CoA reductase. 
Figure 4. Conformation of crystallographic 
simvastatin (Cyan) as compared to the docked 
conformation (Green).
Molecular docking Analysis
To ensure that the ligand orientation and position 
obtained from the docking studies were likely to 
represent valid and reasonable binding modes 
of the inhibitors, the Autodok 4.2 program was 
first validated for the crystal structure used 
(1HW9). The ligand simvastatin was extracted 
and docked back to the corresponding binding 
pocket, to determine the ability of Autodok 
4.2 to reproduce the position orientation of the 
ligand observed in the crystal structure. It was 
observed that Autodok 4.2 generated the optimal 
orientation of the docked simvastatin, close to 
that of the original orientation( figure 5) found 
in the crystal Molecular docking study was 
performed using Autodok 4.2 from Reference 
protein coordinates for docking were obtained 
from the X-ray structure of catalytic portion of 
human HMG-CoA reductase complexed with 
simvastatin (PDB ID: 1HW9). 
Top-ranked ligands were analyzed for protein 
ligand interaction studies based on the 
Comparison of the hydrogen bond interaction 
among the top ranked docked poses with the 
protein and secondly, the analysis of binding 
and docking energies between the docked 
ligand and enzyme. Analysis of docking studies 
on three compounds of N-Acyl Anthranilamide 
and quinazolin-4-one derivatives ( 3d, 3k and 
4b ) showed that all these molecules fit well in 
the active site of HMG-CoA reductase ( figure 
5). These methoxy oxygen atoms of ligands 3d 
and 4b are interacting nitrogen atom of residue 
Lys735 through hydrogen bonding similarly as 
in the binding mode of simvastatin which give 
these ligands a fixed shape in the active site. 
The active site common residues were found to 
be Lys735, Ala751, Ala754, Glu559, Leu853, 
Ala856, Asn755, Leu562 and His752. These 
residues also show close hydrophobic contact 
with the ligands which gives further support to 
this mode of interaction of the ligand-substrate. 
The comparison of binding and docking 
energies also suggests that compound ligand 4b 
has clearly edge over ligand 3d and 3k in the 
binding mode.
Figure 5. Ligand 3k (B), 4b (C), and 3d 
(D) ((green) and simvastatin(purple) are 
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in the binding site of HMG-CoA reductase 
(PDB ID: 1hw9. The protein molecule is 
shown in the ribbon representation, whereas 
docked compounds are illustrated in the stick 
representation. Hydrogen bonds are shown as 













Figure 6. quinazolin-4-one derivatives are 
more potent than their corresponding
N-Acyl Anthranilamide. 
Figure 7. A. Docking of ligand 4b into the 
active site of HMG-CoA reductase (PDB ID: 
1hw9). B. Docking of simvastatin into the 
active site of HMG-CoA reductase (PDB ID: 
1hw9).
Adipogenesis is the process by which 
undifferentiated fibroblasts undergo 
morphological changes and accumulate lipid 
droplets as they become mature adipocytes.1 In 
an effort to control adipose levels in vivo for the 
treatment of obesity and diabetes, researchers 
have identified several genes that regulate 
adipogenesis. 33,34 The 3T3-L1 cell line  has been 
particularly valuable in studying the molecular 
mechanisms underlying adipogenesis, owing to 
the difficulty of isolating primary preadipocytes 
from adipose tissue. The conversion of 3T3-
L1 cells into adipocytes occurs through the 
temporal expression of genes over 6-8 days 
and can be initiated in vitro by the addition of a 
hormone cocktail consisting of dexamethasone, 
3-isobutyl-1- methylxanthine, and insulin 
(commonly referred to as DMI).1 Importantly, 
transcription factors such as the nuclear 
receptors peroxisome proliferator-activated 
receptor-γ (PPARγ) and COUP transcription 
factor 2 (COUP-TFII) have been shown to 
regulate both the differentiation of 3T3-L1 cells 
in vitro and the development of adipose tissue 
in vivo, establishing the relevance of this cell-
line model in the discovery of physiologically 
relevant adipogenesis pathways. Compound 4b 
was showing inhibition of adipogenesis at 10 
µM concentration.
Figure 8. Effect of compound 4b on 
adipogenesis in 3T3-L1 cells.
Conclusion -
In summary, we have demonstrated a simple 
and highly efficient protocol for the synthesis 
of N-acyl anthranilamide and quinazolin-4-
one derivatives via palladium-catalyzed C-C 
coupling of aryl amide with isocyanides for 
the first time, which is clearly different from 
the conventional procedures. The reactions 
are operationally simple and avoid using toxic 
carbon monoxide and acid chloride, which 
must be used in an anhydrous system. Most 
importantly, this transformation may be used 
Chemistry & Biology Interface, 2019, 9, 3, 172-185
Chemistry & Biology Interface Vol. 9 (3), May – June 2019184
to discover new nature products and significant 
pharmaceuticals. We also demonstrated the 
biological potential of these compounds as 
novel HMG-CoA reductase inhibitor. Studies 
aimed at developing related transformations are 
underway.
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